RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Fusion Pharm Stock

Fusion Pharm ROCE 2024

Fusion Pharm ROCE

0

Ticker

FSPM

ISIN

US36113H1005

WKN

A1H9CD

In 2024, Fusion Pharm's return on capital employed (ROCE) was 0, a 0% increase from the 0 ROCE in the previous year.

Fusion Pharm Aktienanalyse

What does Fusion Pharm do?

Fusion Pharm Inc is a well-known company in the agricultural industry that operates in various business sectors. It was founded in 2010 by Scott Dittman with the idea of improving agricultural efficiency through the use of innovative technologies. Fusion Pharm has gradually built different business areas focused on the development and marketing of products for optimizing agriculture. One of Fusion Pharm's core areas is the production of modular cultivation systems for plants that utilize cutting-edge technologies. These systems, called "PharmaCubes," are designed to provide optimal conditions for plants and achieve higher crop yields. They are particularly intended for use in urban spaces and other environments where traditional cultivation methods may not be feasible. The advantage of these systems lies in their scalability, and they are optimized for indoor use. Another important business area for Fusion Pharm is the production of fertilizers and other agricultural chemicals. These products are marketed under the brand name "Agritabs" and are aimed at promoting healthier plant growth and higher crop yields. The agricultural chemicals are made from natural raw materials, making them more environmentally friendly than many other products on the market. They are intended for use in various industries, including agriculture, gardening and landscaping, and the food industry. In addition to manufacturing and supplying cultivation systems, Fusion Pharm also operates in the production and distribution of natural fertilizers and other agricultural chemicals. The company has also undertaken a pilot project for closed-room fish farming and established itself in the aquaculture industry. In recent years, the company has pursued an aggressive acquisition strategy to expand into new business fields. One of these acquisitions was the takeover of the cloud-based software company "CannaCube," which has developed a management system for cannabis cultivation. Through the acquisition of CannaCube, Fusion Pharm has now positioned its portfolio for the growing cannabis industry. The company has made a name for itself in the agricultural industry by optimizing existing processes for sustainable and efficient plant development. With its innovative technology and products, the company contributes to greater efficiency and a more environmentally friendly agricultural industry. Fusion Pharm ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Fusion Pharm's Return on Capital Employed (ROCE)

Fusion Pharm's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Fusion Pharm's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Fusion Pharm's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Fusion Pharm’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Fusion Pharm stock

What is the ROCE (Return on Capital Employed) of Fusion Pharm this year?

The ROCE of Fusion Pharm is 0 undefined this year.

How has the ROCE (Return on Capital Employed) of Fusion Pharm developed compared to the previous year?

The ROCE of Fusion Pharm has increased by 0% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Fusion Pharm?

A high Return on Capital Employed (ROCE) indicates that Fusion Pharm has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Fusion Pharm?

A low ROCE (Return on Capital Employed) can indicate that Fusion Pharm has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Fusion Pharm impact the company?

An increase in the ROCE of Fusion Pharm can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Fusion Pharm affect the company?

A decrease in ROCE of Fusion Pharm can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Fusion Pharm?

Some factors that can affect Fusion Pharm's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Fusion Pharm so important for investors?

The ROCE of Fusion Pharm is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Fusion Pharm take to improve the ROCE?

To improve the ROCE, Fusion Pharm can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Fusion Pharm pay?

Over the past 12 months, Fusion Pharm paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fusion Pharm is expected to pay a dividend of 0 USD.

What is the dividend yield of Fusion Pharm?

The current dividend yield of Fusion Pharm is .

When does Fusion Pharm pay dividends?

Fusion Pharm pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fusion Pharm?

Fusion Pharm paid dividends every year for the past 0 years.

What is the dividend of Fusion Pharm?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fusion Pharm located?

Fusion Pharm is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von Fusion Pharm kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fusion Pharm from 11/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did Fusion Pharm pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Fusion Pharm in the year 2023?

In the year 2023, Fusion Pharm distributed 0 USD as dividends.

In which currency does Fusion Pharm pay out the dividend?

The dividends of Fusion Pharm are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Fusion Pharm

Our stock analysis for Fusion Pharm Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fusion Pharm Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.